Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
Authors:
- 20 August 2021
- journal article
- letter
- Published by Elsevier in Annals of Oncology
- Vol. 32 (11) , 1442-1443
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- Cardiovascular Toxicities of Bruton’s Tyrosine Kinase InhibitorsCurrent Treatment Options in Oncology, 2020
- Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)HemaSphere, 2020
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLNew England Journal of Medicine, 2018
- Ventricular arrhythmias and sudden death in patients taking ibrutinibBlood, 2017